Sign up to our newsletter
and receive exclusive information and discount coupons straight to your inbox


Top news by writer

Daniel Tomas
Tehnology Writer

HEALTH / The daily deal : a neck massager at an unbeatable price
As of this week, helpmeoutDOC has begun offering a series of massively discounted health items for sale. Today it is time to introduce our readers…
July 28, 2016 | 0 comments

Gabriel Rosoga
Medical and Health Writer

BEAUTY & SKIN CARE / Bee venom serums work miracles on skin
Bee venom, when used in small dosis, proves to be a very effective natural medicine, with extremely beneficial impact on the human organism, with particular…
September 8, 2016 | 1 comment

Ion Gireada
Science Writer

HEALTH / Reasons why your brain hears a ringing
Brain activity in people affected by tinnitus is very different from what happens when sound is detected in brains of healthy people, new research uncovered.…
April 27, 2015 | 0 comments

Ionut Popescu
Health and lifestyle writer

HEALTH / Brits oblivious to obesity leading to cancer
British population largely unware of link between obesity and cancer, finds new survey conducted by the organization Cancer Research UK. According to the survey, 75%…
September 9, 2016 | 0 comments

New drug shows promise in fighting brain cancer

by Ion Gireada on 4 March 2015
Health, Medical technology     |      blood-brain barrier,  brain cancer,  glioblastoma,  Trilexium,  TRXE-009



cancer
A new drug developed in Australia shows promise in destroying stubborn brain cancer cells.

A pre-clinical study in the United States confirmed that the drug Trilexium (TRXE-009) can destroy brain cancer cells that resist chemotherapy and cause tumors to return. The drug is effective both in children and adults.

The study, conducted at the Feinstein Institute for Medical Research, studied the effects of the drug on brain cancer cells taken from patients.

Participants in the study had had glioblastoma multiform (GBM), the most common and aggressive type of brain cancer.

“Killing these highly-resistant GBM cancer stem cells is considered to be a fundamental requirement to successfully treating this highly destructive disease,” the drug’s developer, Novogen. “All patient derived cancer cells represented in the library responded to TRXE-009 at clinically relevant doses, suggesting a strong therapeutic potential.”

Novogen developed Trilexium to cross the blood-brain barrier, which blocks most chemotherapeutic drugs from reaching brain tissue.

The company is also collaborating with the Feinstein Institute on different methods to deliver the drug, including by direct injection into cancer cells and intravenously.

Novogen hopes to launch a phase 1 clinical trial of the drug in early 2016. The clinical trials are extremely interesting in the context of previous attempts with TRXE-009 showing high toxicity in other types of pediatric brain cancers.



New drug shows promise in fighting brain cancer



cancer
facebook pinterest google+